Verition Fund Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
VPM
VCM
RRAM
Verition Fund Management's HAE Position: Q1 2026 in Review
Verition Fund Management sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 11,300 shares — an estimated $906K sold.
Verition Fund Management first reported a position in HAE in Q4 2016 and held it in 18 quarters. The position peaked at $2.37M in Q2 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Verition Fund Management reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
- Verition Fund Management sold 11,300 Haemonetics shares in Q1 2026, an estimated $906K.
- Verition Fund Management first reported a position in Haemonetics in Q4 2016 and held it in 18 quarters.
- Verition Fund Management's Haemonetics position peaked at $2.37M in Q2 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.